TNFAIP3 and ductal breast carcinoma in situ: AP20187-activated iFGFR1 robustly increased the expression of TNFAIP3 mRNA in DCIS-iFGFR1 cells, while this increase could be completely blocked by treating cells with FGFR inhibitors LY2874455 [51] and AZD4547 [52] (Fig. 4a).